DA32 Life Science Tech Acquisition
We intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. We are offering Class A ordinary shares. (This is NOT a unit offering; most blank-check or SPAC IPOs are unit offerings.) Our CEO is Steven Kafka, Ph.D., a managing partner at Section 32, a venture […]
July 27, 2021 Read More